FENC

Fennec Pharmaceuticals Inc

Apr 02 • 04:00PM ET

6.42

+0.01 0.16 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY SRPT AGEN XOMA ACAD NBIX PRQR IONS

| Held by: VTI IWM IWN VTWO IWC IWO VTWV RSSL VTWG OMFS

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	14.13%	Shs Outstand	34.16M	Perf Week	-1.38%
Market Cap	221.36M	Forward P/E	7.41	EPS next Y	0.87	Insider Trans	-22.39%	Shs Float	29.61M	Perf Month	-21.71%
Enterprise Value	184.57M	PEG	-	EPS next Q	-0.04	Inst Own	56.15%	Short Float	2.72%	Perf Quarter	-16.62%
Income	-10.10M	P/S	4.96	EPS this Y	152.38%	Inst Trans	9.88%	Short Ratio	5.15	Perf Half Y	-33.06%
Sales	44.64M	P/B	6.18	EPS next Y	372.73%	ROA	-17.48%	Short Interest	0.81M	Perf YTD	-16.62%
Book/sh	1.04	P/C	6.02	EPS next 5Y	-	ROE	-68.24%	52W High	9.92 -35.28%	Perf Year	8.08%
Cash/sh	1.07	P/FCF	-	EPS past 3/5Y	27.71% 14.90%	ROIC	-28.47%	52W Low	4.68 37.18%	Perf 3Y	-22.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	207.52% 204.69%	Gross Margin	91.57%	Volatility	6.22% 7.38%	Perf 5Y	2.47%
Dividend TTM	-	EV/Sales	4.13	EPS Y/Y TTM	-12844.44%	Oper. Margin	-15.11%	ATR (14)	0.49	Perf 10Y	252.90%
Dividend Ex-Date	-	Quick Ratio	6.23	Sales Y/Y TTM	-6.09%	Profit Margin	-22.62%	RSI (14)	40.19	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.37	EPS Q/Q	-179.66%	SMA20	-9.01%	Beta	0.95	Target Price	15.17
Payout	-	Debt/Eq	0.00	Sales Q/Q	73.84%	SMA50	-16.70%	Rel Volume	1.70	Prev Close	6.41
Employees	35	LT Debt/Eq	0.00	Earnings	Mar 24 BMO	SMA200	-21.53%	Avg Volume	156.69K	Price	6.42
IPO	Oct 22, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	-502.84% -6.49%	Trades		Volume	267,076	Change	0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-26	Initiated	B. Riley Securities	Buy	$16
Jan-09-26	Initiated	Piper Sandler	Overweight
Nov-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$9 → $12
Sep-07-22	Initiated	CapitalOne	Overweight	$11
Aug-08-22	Resumed	Craig Hallum	Buy	$14
Jun-05-20	Initiated	Cantor Fitzgerald	Overweight	$18
Oct-11-18	Initiated	Goldman	Buy

Mar-31-26 06:00AM	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.59%
Mar-25-26 08:30AM	Fennec Pharmaceuticals Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-24-26 03:02PM	Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com) -19.19%
01:20PM	Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile)
07:00AM	Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:08AM	Loading…
Mar-18-26 07:08AM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 (GlobeNewswire)
Mar-16-26 08:08AM	Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation (GlobeNewswire)
Mar-05-26 10:00AM	Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline (Zacks)
Mar-04-26 07:05AM	Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute (GlobeNewswire)
Mar-02-26 10:00AM	Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:15AM	Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-26-26 08:15AM	Certara, Inc. (CERT) Q4 Earnings Lag Estimates (Zacks)
Feb-24-26 11:00AM	Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-20-26 07:03AM	Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK in Treating Adults with Head & Neck Cancers (GlobeNewswire)
Feb-12-26 08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More (24/7 Wall St.)
05:44PM	Loading…
Dec-26-25 05:44PM	Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) (GlobeNewswire) +5.48%
Dec-09-25 07:00AM	Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors (GlobeNewswire)
Dec-02-25 07:01AM	Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss (GlobeNewswire)
Nov-26-25 05:59AM	Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-19-25 07:03AM	Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption (GlobeNewswire) -6.51%
Nov-18-25 08:30AM	Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada (GlobeNewswire)
Nov-17-25 04:15PM	Fennec Pharmaceuticals Announces Closing of Offering of Common Shares (GlobeNewswire) +11.32%
Nov-13-25 11:11PM	Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada (GlobeNewswire)
11:07PM	Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares (GlobeNewswire)
05:10PM	Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Fennec Pharmaceuticals Announces Proposed Offering of Common Shares (GlobeNewswire)
04:01PM	Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 06:00PM	Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-30-25 10:00AM	Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
10:19AM	Loading…
Oct-22-25 10:19AM	Are Options Traders Betting on a Big Move in Fennec Pharmaceuticals Stock? (Zacks)
Oct-15-25 04:20AM	New Strong Sell Stocks for Oct. 15th (Zacks) +5.86%
Oct-06-25 09:40AM	Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last? (Zacks)
Sep-19-25 09:43AM	Is the Options Market Predicting a Spike in Adherex Technologies Stock? (Zacks)
Aug-14-25 07:20AM	Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -6.37%
06:08AM	Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update (GlobeNewswire)
Aug-13-25 05:15PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +12.00%
Aug-11-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 (GlobeNewswire)
Aug-07-25 07:05PM	Concentra Group (CON) Matches Q2 Earnings Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-15-25 08:50AM	Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why (Zacks)
Jun-03-25 04:31PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-14-25 10:51AM	The Joint Misses Q1 Earnings Estimates on Rising Expenses (Zacks)
03:07AM	Fennec Pharmaceuticals Inc (FENC) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)
May-13-25 11:33PM	Q1 2025 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
11:06AM	Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions (Zacks)
07:15AM	Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.38%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
May-07-25 05:35PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 09:55AM	Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High? (Zacks)
Apr-10-25 09:35AM	Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround (Zacks)
Mar-21-25 10:21AM	Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? (Zacks)
Mar-11-25 03:00AM	Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:31AM	Q4 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-10-25 06:03AM	Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.19%
Mar-06-25 04:22PM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 (GlobeNewswire)
Feb-07-25 07:00AM	Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany (GlobeNewswire)
Dec-20-24 06:16AM	Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales (GlobeNewswire)
Dec-19-24 06:13AM	Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management (GlobeNewswire)
Dec-12-24 07:01AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-13-24 06:27AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire) +5.91%
Nov-09-24 02:00AM	Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Nov-07-24 06:13AM	Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.92%
Oct-31-24 06:23AM	Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 06:23AM	Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth (GlobeNewswire) +11.56%
Sep-05-24 06:56AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 01:57AM	Q2 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
Aug-13-24 06:05AM	Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.40%
Aug-06-24 04:31PM	Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire)
Aug-05-24 06:26AM	Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director (GlobeNewswire)
Jul-29-24 06:15AM	3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! (InvestorPlace)
Jul-15-24 08:32AM	Implied Volatility Surging for Fennec (FENC) Stock Options (Zacks)
Jul-01-24 06:00AM	Fennec Pharmaceuticals Announces Management Change (GlobeNewswire)
Jun-25-24 04:35PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-15-24 08:44AM	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating (MT Newswires)
May-14-24 10:53AM	FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -26.75%
07:20AM	Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue (MT Newswires)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 06:15PM	Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 (GlobeNewswire)
Apr-23-24 08:01AM	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing (MT Newswires)
Apr-05-24 07:00PM	Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-27-24 07:00PM	Chief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-26-24 01:00AM	Chief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-22-24 09:49AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:04AM	Q4 2023 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-21-24 02:52PM	FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:00AM	Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-19-24 10:14AM	Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up (Zacks)
06:01AM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 (GlobeNewswire)
Mar-17-24 09:00PM	Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand (GlobeNewswire)
Feb-29-24 07:04AM	Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Feb-01-24 05:55AM	FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin (GlobeNewswire)
Jan-06-24 03:01AM	Insider Sell: CFO Robert Andrade Sells 30,000 Shares of Fennec Pharmaceuticals Inc (GuruFocus.com)
Dec-05-23 05:55AM	Fennec Announces Incremental $5 Million Investment from Petrichor (GlobeNewswire)

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cioffi Christiana Marie	Chief Strategy Officer	Mar 31 '26	Option Exercise	0.00	17,264	0	21,964	Apr 02 04:05 PM
Cioffi Christiana Marie	Chief Strategy Officer	Mar 28 '26	Option Exercise	0.00	1,901	0	23,865	Apr 02 04:05 PM
Hackman Jeffrey S.	Chief Executive Officer	Mar 31 '26	Option Exercise	0.00	17,854	0	46,564	Apr 02 04:05 PM
Hackman Jeffrey S.	Chief Executive Officer	Mar 28 '26	Option Exercise	0.00	13,943	0	60,507	Apr 02 04:05 PM
Raykov Rosty	Director	Apr 01 '26	Option Exercise	2.45	15,598	38,215	124,802	Apr 02 04:05 PM
Raykov Rosty	Director	Apr 01 '26	Sale	6.31	10,946	69,069	113,856	Apr 02 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Mar 31 '26	Option Exercise	0.00	18,627	0	18,627	Apr 02 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Mar 28 '26	Option Exercise	0.00	2,052	0	20,679	Apr 02 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 31 '26	Option Exercise	0.00	16,937	0	273,593	Apr 02 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 28 '26	Option Exercise	0.00	12,270	0	285,863	Apr 02 04:05 PM
Evans Terry L	Chief Commercial Officer	Mar 31 '26	Option Exercise	0.00	18,627	0	18,627	Apr 02 04:05 PM
Evans Terry L	Chief Commercial Officer	Mar 28 '26	Option Exercise	0.00	2,052	0	20,679	Apr 02 04:05 PM
ROSTISLAV RAYKOV	Director	Apr 01 '26	Proposed Sale	6.31	10,946	69,073		Apr 01 04:38 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 26 '26	Option Exercise	5.10	13,072	66,667	256,656	Mar 26 04:30 PM
Cioffi Christiana Marie	Chief Strategy Officer	Mar 26 '26	Option Exercise	4.23	4,700	19,881	4,700	Mar 26 04:29 PM
Raykov Rosty	Director	Mar 02 '26	Option Exercise	2.45	15,598	38,215	114,075	Mar 03 04:05 PM
Raykov Rosty	Director	Mar 02 '26	Sale	8.36	10,079	84,260	103,996	Mar 03 04:05 PM
ROSTISLAV RAYKOV	Director	Mar 02 '26	Proposed Sale	8.37	10,079	84,354		Mar 02 05:07 PM
Hackman Jeffrey S.	Chief Executive Officer	Feb 18 '26	Option Exercise	0.00	13,710	0	28,710	Feb 19 06:44 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Feb 18 '26	Option Exercise	0.34	29,735	9,996	242,393	Feb 19 06:43 PM
Raykov Rosty	Director	Feb 02 '26	Option Exercise	2.45	15,598	38,215	108,826	Feb 02 04:54 PM
Raykov Rosty	Director	Feb 02 '26	Sale	7.76	10,349	80,308	98,477	Feb 02 04:54 PM
ROSTISLAV RAYKOV	Director	Feb 02 '26	Proposed Sale	7.76	10,349	80,339		Feb 02 04:32 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 23 '26	Option Exercise	2.45	10,000	24,500	211,100	Jan 23 04:56 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 15 '26	Option Exercise	2.45	10,000	24,500	201,100	Jan 15 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 07 '26	Option Exercise	2.45	14,184	34,751	191,100	Jan 07 04:28 PM
Raykov Rosty	Director	Jan 02 '26	Option Exercise	2.45	15,598	38,215	98,332	Jan 05 04:05 PM
Raykov Rosty	Director	Jan 02 '26	Sale	7.60	10,312	78,371	88,020	Jan 05 04:05 PM
ROSTISLAV RAYKOV	Director	Jan 02 '26	Proposed Sale	7.61	10,312	78,471		Jan 02 04:19 PM
Southpoint Capital Advisors LP	10% Owner	Dec 24 '25	Sale	7.50	1,000,000	7,500,000	2,744,741	Dec 29 04:34 PM
Raykov Rosty	Director	Dec 05 '25	Sale	7.54	10,000	75,400	77,526	Dec 05 06:41 PM
ROSTISLAV RAYKOV	Director	Dec 05 '25	Proposed Sale	7.54	10,000	75,444		Dec 05 05:13 PM
Southpoint Capital Advisors LP	10% Owner	Nov 18 '25	Sale	8.79	19,341	170,048	3,744,741	Nov 20 04:07 PM
Southpoint Capital Advisors LP	10% Owner	Nov 14 '25	Sale	8.00	160,100	1,280,432	3,850,000	Nov 17 08:42 PM
Southpoint Capital Advisors LP	10% Owner	Nov 17 '25	Sale	8.79	85,918	755,193	3,764,082	Nov 17 08:42 PM
Raykov Rosty	Director	Nov 05 '25	Sale	8.10	10,000	81,000	82,318	Nov 06 04:10 PM
ROSTISLAV RAYKOV	Director	Nov 05 '25	Proposed Sale	8.11	10,000	81,082		Nov 05 04:28 PM
RALLIS CHRIS A	Director	Oct 10 '25	Option Exercise	1.23	4,062	4,996	58,854	Oct 14 04:10 PM
RALLIS CHRIS A	Director	Oct 10 '25	Sale	9.24	1,775	16,401	57,079	Oct 14 04:10 PM
CHRIS A RALLIS	Director	Oct 10 '25	Proposed Sale	9.24	1,775	16,401		Oct 10 04:02 PM
Southpoint Capital Advisors LP	10% Owner	Oct 07 '25	Sale	9.59	26,900	257,893	4,050,314	Oct 09 05:31 PM
Southpoint Capital Advisors LP	10% Owner	Oct 09 '25	Sale	9.35	20,609	192,614	4,010,100	Oct 09 05:31 PM
Southpoint Capital Advisors LP	10% Owner	Oct 08 '25	Sale	9.47	19,605	185,722	4,030,709	Oct 09 05:31 PM
Raykov Rosty	Director	Oct 08 '25	Option Exercise	2.45	4,609	11,292	87,110	Oct 08 05:08 PM
Raykov Rosty	Director	Oct 06 '25	Sale	9.78	10,000	97,800	82,501	Oct 06 06:22 PM
ROSTISLAV RAYKOV	Director	Oct 06 '25	Proposed Sale	9.79	10,000	97,868		Oct 06 04:27 PM
Raykov Rosty	Director	Sep 05 '25	Option Exercise	2.45	36,207	88,707	87,293	Sep 08 06:05 PM
ROSTISLAV RAYKOV	Director	Sep 04 '25	Proposed Sale	8.92	10,000	89,220		Sep 04 04:37 PM
Raykov Rosty	Director	Sep 04 '25	Sale	8.92	10,000	89,200	51,086	Sep 04 04:10 PM
Raykov Rosty	Director	Aug 05 '25	Sale	8.09	10,000	80,900	55,878	Aug 05 05:33 PM
ROSTISLAV RAYKOV	Director	Aug 05 '25	Proposed Sale	8.09	10,000	80,933		Aug 05 04:14 PM
RALLIS CHRIS A	Director	Jul 07 '25	Option Exercise	2.35	2,127	4,998	55,911	Jul 07 05:31 PM
RALLIS CHRIS A	Director	Jul 07 '25	Sale	8.71	1,119	9,746	54,792	Jul 07 05:31 PM
Raykov Rosty	Director	Jul 03 '25	Sale	8.61	10,000	86,100	60,670	Jul 07 04:30 PM
ROSTISLAV RAYKOV	Director	Jul 03 '25	Proposed Sale	8.61	10,000	86,102		Jul 03 02:01 PM
Raykov Rosty	Director	Jun 05 '25	Sale	7.78	10,000	77,800	65,462	Jun 06 04:20 PM
ROSTISLAV RAYKOV	Director	Jun 05 '25	Proposed Sale	7.78	10,000	77,781		Jun 05 04:31 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	May 22 '25	Option Exercise	5.10	8,220	41,922	158,520	May 23 04:20 PM
Hackman Jeffrey S.	Chief Executive Officer	May 19 '25	Buy	6.99	13,965	97,615	15,000	May 19 05:42 PM
Hackman Jeffrey S.	Chief Executive Officer	May 16 '25	Buy	6.75	1,035	6,986	1,035	May 19 05:42 PM
Raykov Rosty	Director	May 16 '25	Sale	6.78	16,667	113,002	70,254	May 19 04:30 PM
Raykov Rosty	Director	May 16 '25	Proposed Sale	6.01	16,667	100,169		May 16 05:21 PM
Raykov Rosty	Director	May 05 '25	Sale	6.31	10,000	63,100	53,587	May 05 06:23 PM
ROSTISLAV RAYKOV	Director	May 05 '25	Proposed Sale	6.31	10,000	63,078		May 05 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FENC

Fennec Pharmaceuticals Inc

Upgrade your Finviz experience